

          -  Known hypersensitivity to HCQ or other 4-aminoquinoline compounds

          -  Known hypersensitivity to azithromycin or other azalide or macrolide antibiotics

          -  Currently hospitalized

          -  Signs of respiratory distress prior to randomization, including respiratory rate >24

          -  Current medications include HCQ

          -  Concomitant use of other anti-malarial treatment or chemoprophylaxis

          -  History of retinopathy of any etiology

          -  Psoriasis

          -  Porphyria

          -  Chronic kidney disease (Stage IV or receiving dialysis)

          -  Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes
             <1500) or thrombocytopenia (<100 K)

          -  Concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen

          -  Known cirrhosis

          -  Known personal or family history of long QT syndrome

          -  History of coronary artery disease with a history of graft or stent

          -  History of heart failure, Class 2 or greater using the New York Heart Association
             functional class

          -  Taking medications associated with prolonged QT such as antipsychotic medications or
             antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop
             during the trial

          -  Taking warfarin (Coumadin or Jantoven)

          -  Known history of glucose-6-phosphate-dehydrogenase deficiency

          -  History of myasthenia gravis
      